Novoseven Related Published Studies
Well-designed clinical trials related to Novoseven (Coagulation Factor Viia)
Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. [2010.12]
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. [2008.03]
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. [2005.05]
Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. [2005.02]
Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. [2004.07]
Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men. [2003.05]
Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. [2003.04]
Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. [2002.10]
Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. [2002.05]
Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. [2002.01]
The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. [2000.04]
Heparin blunts endotoxin-induced coagulation activation. [1999.12.21]
Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. [1999.10]
The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. [1998.11]
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. [1998.11]
Effects of dietary fat quality and quantity on postprandial activation of blood coagulation factor VII. [1997.11]
Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. [1996.08]
Well-designed clinical trials possibly related to Novoseven (Coagulation Factor Viia)
Recombinant factor VIIa for the prevention and treatment of bleeding in patients
without haemophilia. [2012]
Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. [2011.10]
Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. [2011.07]
Neurosurgical outcomes after intracerebral hemorrhage: results of the Factor Seven for Acute Hemorrhagic Stroke Trial (FAST). [2011.07]
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial. [2011.04.28]
[Intensive care management [corrected] of patients with intracerebral hemorrhage]. [2011.04]
Neurosurgical outcomes after intracerebral hemorrhage: results of the Factor
Seven for Acute Hemorrhagic Stroke Trial (FAST). [2011]
Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding: analysis of the F7 liver-1288 study population. [2010.12]
Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study. [2010.11]
Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. [2010.09]
Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. [2010.08.05]
Global differences in causes, management, and survival after severe trauma: the recombinant activated factor VII phase 3 trauma trial. [2010.08]
Prolonged prothrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes. [2010.07]
Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. [2010.02.01]
Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial. [2010.02]
Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. [2010.01]
The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. [2009.12]
Evidence-based Emergency Medicine/Critically Appraised Topic. The efficacy of recombinant activated factor VII in severe trauma. [2009.11]
Uncontrolled bleeding in surgical patients: the role of recombinant activated factor VIIa. [2009.08]
Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. [2009.07.07]
A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. [2009.06]
Density and shape as CT predictors of intracerebral hemorrhage growth. [2009.04]
Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. [2009.03.20]
Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. [2009.02]
Depressed mood after intracerebral hemorrhage: the FAST trial. [2009]
Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. [2008.12.03]
Evidence for the use of recombinant factor VIIa in the prevention and treatment of bleeding in patients without hemophilia. [2008.07]
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. [2008.06]
Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. [2008.05.15]
Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. [2008.05]
Recombinant factor VIIA in traumatic intracerebral hemorrhage: results of a dose-escalation clinical trial. [2008.04]
The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework. [2008.04]
An evaluation of eptacog alfa in nonhaemophiliac conditions. [2008]
Association between disability measures and short-term health care costs following intracerebral hemorrhage. [2008]
Reducing the risk of ICH enlargement. [2007.10.15]
Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. [2007.10.01]
Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. [2007.10.01]
[Acute stroke therapy. Current developments] [2007.10]
[Acute stroke therapy : Current developments.] [2007.09.20]
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. [2007.09.01]
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. [2007.08.08]
The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. [2007.07]
Fenoldopam and gastric tonometry during orthotopic liver transplantation. [2007.07]
Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. [2007.06.26]
The solid fat content of stearic acid-rich fats determines their postprandial effects. [2007.06]
Recombinant Factor VIIa: Review of Current "Off License" Indications and Implications for Practice. [2007.04]
Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study. [2007.04]
Various Local Hemostatic Agents with Different Modes of Action; an in vivo Comparative Randomized Vascular Surgical Experimental Study. [2007.03]
Determinants of intracerebral hemorrhage growth: an exploratory analysis. [2007.03]
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. [2007.02]
Salmeterol enhances pulmonary fibrinolysis in healthy volunteers. [2007.01]
Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage. [2007]
Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial. [2007]
Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. [2006.11]
Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. [2006.10]
Recombinant factor VIIa and the surgical patient. [2006.08]
Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. [2006.07]
Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. [2006.04.25]
Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. [2006.04]
Modern treatment options for intracerebral hemorrhage. [2006.03]
Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. [2006.02]
Ultra-early Hemostatic Therapy for Acute Intracerebral Hemorrhage. [2006.01]
Assessing Efficacy and Therapeutic Claims in Emerging Indications for Recombinant Factor VIIa: Regulatory Perspectives. [2006.01]
Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. [2006]
Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. [2006]
Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. [2006]
Potential applicability of recombinant factor VIIa for intracerebral hemorrhage. [2005.12]
Ultra-early hemostatic therapy for primary intracerebral hemorrhage: a review. [2005.12]
Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. [2005.11]
Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. [2005.11]
Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. [2005.09]
Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. [2005.08]
Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. [2005.08]
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. [2005.07]
No effect of folic acid supplementation in the course of 1 year on haemostasis markers and C-reactive protein in older adults. [2005.07]
Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. [2005.07]
A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. [2005.06]
Recombinant activated factor VII for acute intracerebral hemorrhage. [2005.02.24]
Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. [2005.01]
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. [2004.10]
Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X. [2003.11]
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. [2003.06.18]
Influence of triacylglycerol structure on the postprandial response of factor VII to stearic acid-rich fats. [2003.04]
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. [2002.11.12]
|
